Clinical Trial Update: Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849) [Phase 3]

View source ↗

Summary

A long-term Phase 3 trial evaluating ipragliflozin added to sitagliptin in Japanese participants with type 2 diabetes mellitus has completed with posted results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Sitagliptin (sitagliptin)
• ipragliflozin (ipragliflozin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2018-03-14